Methamphetamine (METH) is one of the most addictive and neurotoxic drugs in existence whose societal impact is on the rise. The molecular mechanisms underlying the effects of METH on the dopamine transporter (DAT), the major molecular target of several psychoactive drugs, are poorly understood. Importantly, due to structural similarities between METH and amphetamine (AMPH), METH regulation of DAT is generally inferred from studies characterizing AMPH. Therefore, the biophysical properties and underlying molecular mechanisms of METH-exposed DAT are virtually unknown. METH primarily exerts its addictive properties by producing large elevations in extracellular striatal dopamine (DA). The DAT is a neurotransmitter transporter that regulates the magnitude and duration of synaptic signaling by clearing released DA from the synapse. However, DAT also mediates DA release via reverse transport (efflux) and can operate in a channel mode, which dramatically increases DA flux. METH mediates DA efflux via DAT, and revealing the mechanisms for this efflux is critical in understanding METH addiction and neurotoxicity. The proposed studies will test the hypotheses that METH regulates extracellular DA by: stabilizing DAT channel mode activity to increase DA efflux, decreasing DA uptake, and/or modifying DAT cell surface distribution in a voltage- and phosphorylation-dependent manner, and that these coordinated events account for the highly addictive nature and neurotoxicity of METH when compared with structural congeners, like AMPH. We will test these hypotheses, all of which are supported by promising preliminary data, with the following specific aims: 1) Determine the biophysical and molecular mechanisms underlying METH-induced DA efflux relative to AMPH, 2) Test the hypothesis that METH targets a phosphorylated state of DAT to regulate DA efflux, substrate uptake, and DAT surface distribution, 3) Compare METH-induced with AMPH-induced current-to-substrate ratios 4) Measure METH-provoked DAT surface mobility as a function of DAT N-terminal phosphorylation. We will achieve these aims in midbrain dopaminergic neurons and DAT expressing oocytes using whole-cell, cell-attached, and cell-detached patch clamp with simultaneous amperometry to measure DA efflux;and use the fluorescent substrate ASP+ to monitor DAT-dependent uptake. We anticipate that our findings will identify mechanisms for novel therapeutic strategies that may prevent or reverse METH toxicity/addiction, as well as suggest unique targets for other neurological diseases whose etiology includes dysfunction of the dopaminergic system.

Public Health Relevance

Chronic use of methamphetamine can lead to addiction, severe neurological and psychiatric impairment, as well as pronounced neurodegeneration. Due to structural similarities regulation of dopamine transporter (DAT) is generally inferred from studies characterizing other amphetamines. Our proposed studies 1) will clarify the molecular mechanisms of methamphetamine-induced dopamine efflux via DAT, and 2) differentiate methamphetamine from its well-characterized, less neurotoxic congener, amphetamine that are valuable for identification of therapeutic strategies for the treatment of methamphetamine addiction and other neurodegenerative diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA026947-04
Application #
8220859
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Pilotte, Nancy S
Project Start
2010-04-01
Project End
2015-01-31
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
4
Fiscal Year
2012
Total Cost
$295,531
Indirect Cost
$77,687
Name
University of Florida
Department
Neurosciences
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Sambo, Danielle O; Lebowitz, Joseph J; Khoshbouei, Habibeh (2018) The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction. Pharmacol Ther 186:152-167
Mackie, Phillip; Lebowitz, Joe; Saadatpour, Leila et al. (2018) The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease. Brain Behav Immun 70:21-35
Siciliano, Cody A; Saha, Kaustuv; Calipari, Erin S et al. (2018) Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation. J Neurosci 38:484-497
Miller, Douglas R; Shaerzadeh, Fatemeh; Phan, Leah et al. (2018) HIV-1 Tat regulation of dopamine transmission and microglial reactivity is brain region specific. Glia 66:1915-1928
Salvatore, Michael F; Nejtek, Vicki A; Khoshbouei, Habibeh (2018) Prolonged increase in ser31 tyrosine hydroxylase phosphorylation in substantia nigra following cessation of chronic methamphetamine. Neurotoxicology 67:121-128
Butler, Brittany; Sambo, Danielle; Khoshbouei, Habibeh (2017) Alpha-synuclein modulates dopamine neurotransmission. J Chem Neuroanat 83-84:41-49
Sacino, Amanda N; Brooks, Mieu M; Chakrabarty, Paramita et al. (2017) Proteolysis of ?-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. J Neurochem 140:662-678
Gaskill, Peter J; Miller, Douglas R; Gamble-George, Joyonna et al. (2017) HIV, Tat and dopamine transmission. Neurobiol Dis 105:51-73
Ayers, Jacob I; Diamond, Jeffrey; Sari, Adriana et al. (2016) Distinct conformers of transmissible misfolded SOD1 distinguish human SOD1-FALS from other forms of familial and sporadic ALS. Acta Neuropathol 132:827-840
Richardson, Ben D; Saha, Kaustuv; Krout, Danielle et al. (2016) Membrane potential shapes regulation of dopamine transporter trafficking at the plasma membrane. Nat Commun 7:10423

Showing the most recent 10 out of 26 publications